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Abstract: Introduction: The safety and efficacy of fluticasone furoate nasal spray (FFNS) for the symptoms of seasonal 
and perennial allergic rhinitis have been previously demonstrated in several clinical studies. The objective of this pilot 
study was to compare the efficacy and safety of FFNS 110 mcg once daily with placebo in patients with irritant (non-
allergic) rhinitis triggered predominantly by air pollution. 
Methods: This was a randomized, double-blind, placebo-controlled, 4-week study of subjects in Thailand with irritant 
rhinitis who received either FFNS 110 mcg (N=53) or placebo (N=49) once-daily. Subjects with a 2 year history of air 
pollution as their predominant rhinitis trigger, negative skin test to local seasonal/perennial allergens, positive histamine 
skin test, and normal sinus radiograph were enrolled if they met minimum reflective total nasal symptom score (rTNSS) 
4.5 (maximum=9) and a nasal congestion score of 2 (maximum =3). All were assessed for nasal eosinophilia at study 
entry and completion. Air quality was monitored throughout the study. The primary efficacy endpoint was the mean 
change from baseline over the treatment period in daily rTNSS, the average of the morning and evening rTNSS. The key 
secondary measure was the mean change from baseline over the entire treatment period in morning pre-dose instantaneous 
total nasal symptom score (iTNSS). 
Results: The Air Quality Index (AQI) during the study generally did not reach unhealthy levels. Baseline daily rTNSS 
scores were similar between treatment groups (FFNS=6.7; placebo=6.4). The least square mean change from baseline in 
rTNSS was -2.17 and -2.10 for FFNS and placebo, respectively, with a difference of -0.065 (p=0.845). Gradual 
improvements were seen in both treatment groups for iTNSS; however, the treatment difference (-0.075) was not 
statistically significant (p=0.827). Additionally, there were no statistically significant differences between treatment 
groups for AM and PM rTNSS, individual nasal symptoms, daily reflective, AM and PM reflective and AM pre-dose 
instantaneous total ocular symptom scores (TOSS) or individual ocular symptom scores. Nasal cytology at baseline found 
more than two-thirds of subjects had <20% eosinophils. Adverse events were few and similar between groups and noted 
as mild in intensity. 
Conclusion: Subjects receiving FFNS had similar improvement to placebo in their rhinitis symptoms. The lack of a 
treatment effect may be in part due to the overall good air quality present throughout the study or an insufficient dose or 
duration of FFNS. The safety findings showed FFNS 110 mcg once daily to be well tolerated. 
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INTRODUCTION 
  Rhinitis is a common disorder affecting 10% to 30% of 
all adults and as many as 40% of children [1-5] with Efficacy and Safety of Once Daily Fluticasone Furoate Nasal Spray  The Open Respiratory Medicine Journal, 2010, Volume 4    93 
symptoms that include rhinorrhea, congestion, sneezing, 
post-nasal drip, and ocular and nasal itching. When assessed 
immunologically, rhinitis is divided into allergic (IgE-
dependent) and non-allergic (IgE-independent) etiologies. 
Research into the cause and treatment of allergic rhinitis is 
abundant in the medical literature; however, nonallergic 
rhinitis (NAR) research has been constrained by a meager 
understanding of the pathophysiology and inconsistent 
categorization of the various NAR conditions and their 
definitions. This disparity in the medical science creates a 
unique problem in clinical practice as non-allergic rhinitis 
may occur in up to 25% of rhinitis sufferers and contribute to 
symptoms in as many as 60% (‘mixed rhinitis’) [6-8]. 
  NAR is a general term for chronic perennial nasal 
conditions that can be categorized into many forms, for 
instance the imbalance of neural innervations, vasomotor 
rhinitis (VMR), or irritant rhinitis. The majority of patients 
with NAR are thought to have VMR or non-allergic rhinitis 
with eosinophilia syndrome (NARES). Using immunologic 
and cytologic features to further categorize NAR, irritant 
rhinitis may be considered a non-inflammatory, non-allergic 
subclass of VMR [7]. Airborne irritants and changes in the 
weather are considered by some to be the two primary 
categories of triggers for VMR. Airborne irritants include 
chemicals, glues, solvents, perfumes, offensive odors, 
pollution, and smoke. Weather and temperature changes 
include fluctuations in temperature, humidity, barometric 
pressure, or air movements [9,10]. 
  An alternative classification scheme for NAR based on 
etiology considers irritant-induced rhinitis a discrete entity 
from VMR with at least five cited causes or types of 
irritants: dry air, gustatory (food-induced), bright light, 
occupational, and air pollution [7,11]. This scheme is in 
alignment with the US Food and Drug Administration’s 
(FDA) position that VMR is predominantly triggered by 
changes in the weather and irritant rhinitis is a distinct form 
of NAR [12]. The FDA’s position formed the basis for 
selecting a study population of subjects with irritant rhinitis 
whose symptoms are primarily triggered by respiratory 
irritants. 
  Air pollution is a common irritant most people have 
encountered at some time in occupational exposure, the 
home, or the outdoor environment. The majority of air 
pollution is caused by the burning of fossil fuels and the 
resultant pollutants of nitrogen oxides, carbon monoxide, 
sulfur dioxides and various particulate matter [11]. 
Atmospheric breakdown of nitrogen oxides to ozone, in 
particular, has been a significant problem in the warmer 
months necessitating daily reporting of levels as a warning 
for the elderly and people with respiratory disease. Studies of 
human exposure to air pollution have been limited for ethical 
reasons by the known toxicity of air contaminants, the 
particle concentrations necessary to emulate poor conditions, 
and the duration of experimental exposures that needed to 
correlate with actual exposure. However, data from small 
studies of various pollutants, some in concentrations found 
in urban western areas, show pollutants may alter nasal 
function and produce nasal symptoms [13,14]. Moreover, 
chronic rhinitis, regardless of immunologic origin, is a potent 
risk factor for the development of asthma. 
  Fluticasone furoate nasal spray (FFNS) has been studied 
extensively in allergic disease and found to demonstrate 
consistent efficacy and safety in seasonal as well as 
perennial allergic rhinitis. Two studies of VMR triggered by 
weather/temperature changes were conducted to assess the 
efficacy of FFNS in non-allergic disease [9]. However, 
neither study found a significant difference from placebo for 
any measure of efficacy. The authors concluded that VMR 
may be a distinct disease variant which is refractory to 
treatment with intranasal steroids. The goal of this pilot 
study was to investigate the efficacy of FFNS in a different 
subset of NAR, subjects with symptoms attributable to air 
pollution occurring in the urban areas of Thailand. 
MATERIALS AND METHODOLOGY 
Patients and Study Design 
  This 4-week, Phase IIa, randomized, double-blind, 
placebo-controlled, parallel-group, multicenter study 
(FFR111158) was conducted in Thailand at 7 study centers 
from March 2008 through February 2009. The protocol and 
one protocol amendment were approved by the individual 
centers’ ethics committees. The study was conducted in 
accordance with good clinical practice and the Declaration of 
Helsinki with written informed consent being obtained from 
each subject or the subject’s parent/guardian if the subject 
was <18 years old. The study consisted of a 2-week 
screening period, a 4-week treatment period, and a 3- to 5-
day follow-up telephone call after treatment ended. The 
study design is shown in Fig. (1). 
Assessments 
  Subjects 12 years of age and older who satisfied the entry 
criteria and did not meet the exclusion criteria (nasal 
obstruction, septal perforation, recent nasal surgery, nasal 
infections) entered a screening period for a minimum of 7 
days and a maximum of 14 days. Inclusion criteria required 
subjects to identify air pollution as the predominant trigger 
that made their rhinitis symptoms worse. To establish this, 
subjects completed an irritant rhinitis trigger questionnaire at 
Visit 1 where they were first asked to select their 
predominant trigger from three types of irritants (air 
pollution, wind/temperature triggers, and strong odors), then 
identify specific triggers within those three groups. 
  Inclusion criteria also included a negative skin prick test 
to local seasonal and perennial allergens, a positive 
histamine control skin prick test, and a normal sinus 
radiograph (Waters view) to rule out sinusitis. A nasal swab 
was also performed using a Rhino-probe™ Curette for the 
purpose of evaluating nasal cytology for treatment 
stratification if the subject met randomization criteria. 
Samples were analyzed by Quest Diagnostics Clinical Trials 
Laboratory (Van Nuys, California). 
  During the screening period, subjects scored three nasal 
(rhinorrhea, nasal congestion, post-nasal drip) and three 
ocular symptoms (eye itching/burning, eye tearing/watering, 
and eye redness) each morning and evening on a paper diary 
card in order to determine eligibility for randomization. 
Symptom ratings were performed with respect to the 
presence/severity of symptoms at the moment in the morning 
just prior to dosing (instantaneous rating, [i]) and over the 
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assessment for the previous 12 hours was also conducted in 
the evening (PM). The three individual reflective nasal and 
ocular symptom scores were combined to obtain an AM and 
PM reflective total nasal symptom score (AM rTNSS, PM 
rTNSS) and total ocular symptom score (AM rTOSS, PM 
rTOSS), respectively. These two scores were then averaged 
to obtain a daily reflective total nasal (daily rTNSS) and total 
ocular symptom score (daily rTOSS). Similarly, the 
instantaneous pre-dose morning scores were summed to 
obtain an instantaneous predose TOSS (AM pre-dose 
iTOSS). The rating scale for symptom assessment was based 
on a widely used, 4-point categorical scale of 0 to 3 (none, 
mild, moderate, severe) [15]. 
  Randomization criteria at Visit 2 required subjects to 
have an average of 4.5 (maximum =9) for the last 8 
reflective TNSS assessments, an average of 2 (maximum 
=3) for the last 8 reflective nasal congestion assessments, 
and an 80% compliance with their diary card entries over the 
span of their screening period. Subjects who fulfilled the 
randomization criteria were randomly assigned in a 1:1 ratio 
to receive either FFNS 110 mcg once daily or vehicle 
placebo nasal spray once daily with the first dose being 
administered in the clinic following device demonstration. 
Subjects were stratified into two groups based on nasal 
cytology: those with eosinophils constituting 5% or <5% of 
nasal white blood cells. 
  Subjects continued their nasal and ocular ratings 
throughout the remainder of the study and returned to the 
clinic weekly for four weeks (Visits 3 to 6) during the 
treatment period. Subjects were instructed not to take any 
anti-allergy/anti-rhinitis medication during the screening or 
treatment periods of the study and no rhinitis rescue 
medication was allowed during the study. Medications 
known to produce allergy symptoms, such as congestion, 
were not allowed. Use of face masks (e.g., used for 
protection from air pollution), continuous positive airflow 
pressure, saline nasal sprays and lavages, eye drops, and 
local, herbal and homeopathic treatments were also 
prohibited. Daily air quality data from Thailand’s 
Environmental Pollution Control website was obtained for 
the period of the study along with air quality data for the 
previous 12 months. Subjects documented the amount of 
time they spent indoors and outdoors, including how much 
time was spent in air conditioned environments. Study drug 
compliance, any medical conditions they experienced, and 
any concomitant medications they took were also recorded 
on diary cards. 
Statistical Analysis 
  As this was a small pilot study, the study was not 
powered to test for a treatment difference. A sample size of 
100 subjects (50 per arm) was used to provide an estimated 
mean treatment difference between FFNS and placebo for 
the primary efficacy endpoint, the mean change from 
baseline in the daily rTNSS over Weeks 1 through 4. With 
this sample size, the precision for the estimated mean 
treatment difference (half the width of the 95% confidence 
interval) was expected to be 0.666, assuming a standard 
deviation of 1.7 which was based on the previous VMR 
studies where the same assessment ratings were used [9]. 
  The primary efficacy analysis was performed using 
analysis of covariance, adjusting for baseline value, baseline 
nasal eosinophil count, age, and gender. 
RESULTS 
Patients 
  A total of 102 subjects were randomized and received at 
least one dose of study treatment. Mean compliance with 
treatment over the 4 week treatment was 94.1% for FFNS 
and 98.6% for placebo. Demographic and baseline 
characteristics were similar between the treatment and 
placebo groups (Table 1 ). As the study was conducted in 
Thailand, all subjects were Asian and the majority classified 
themselves as being of South East Asian heritage. 
Table 1.  Patient Demography and Baseline Characteristics 
 
  FFNS 110 mcg  
QD (N=53) 
Placebo  
(N=49) 
Total  
(N=102) 
Mean Age, years (SD) 
Range  
37.1 (12.78) 
12 - 58 
35.9 (10.89) 
18 - 64 
36.6 (11.87) 
12 - 64 
Gender, n (%) 
Female 
Male 
 
33 (62) 
20 (38) 
 
37 (76) 
12 (24) 
 
70 (69) 
32 (31) 
 
 Table  2 shows the specific triggers noted by the subjects 
in each group. Eighty-seven percent (87%) of subjects 
enrolled in the study reported all 3 categories of triggers. 
  Air quality data during the study was obtained from 
Thailand’s Pollution Control Department website, which is 
operated by the Ministry of Natural Resources and the 
Environment. The study was originally planned to coincide with 
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the dry winter months when greater pollution is typically 
present. However, delays in site ethical approvals resulted in a 
March 2008 start for the study. The wet season in Thailand 
typically runs from June to October. The Air Quality Index 
(AQI) ranged as high as 110 on daily ratings, however, at no 
time did it exceed a weekly mean AQI of 100, the lower end of 
the range defined as unhealthy for sensitive groups (Fig. 2). On 
average, subjects in both treatment groups spent approximately 
six hours daily inside. In addition, subjects spent at least eight 
hours each day outside; however, subjects in the FFNS group 
spent 0.5 – 1.5 hours longer outside compared with subjects in 
the placebo group. 
Efficacy 
Primary Endpoint 
  The primary efficacy measure was the mean change from 
baseline in the reflective total nasal symptom score (rTNSS) 
over the entire treatment period (weeks 1 – 4). At baseline, 
the mean daily rTNSS was similar between the two groups 
(Table  3). A gradual improvement was seen in both 
treatment groups over each week in the study, with slightly 
greater improvements in subjects receiving FFNS (Fig. 3). 
However, the treatment difference over Weeks 1 through 4 
was not statistically significant (Table 3). 
Secondary Endpoints 
  A key secondary efficacy measure was the mean change 
from baseline over weeks 1 through 4 in morning pre-dose 
instantaneous total nasal symptom score (iTNSS). As with the 
daily rTNSS, a gradual improvement was seen in both 
treatments groups; however, the mean treatment difference (-
0.075) was not statistically significant (p=0.827). Additionally, 
there were no statistically significant differences between 
treatment groups for AM and PM rTNSS, individual nasal 
symptoms (rhinorrhea, nasal congestion or post-nasal drip), the 
reflective and instantaneous scores for TOSS, or the individual 
ocular symptom scores (eye itching/burning, eye 
tearing/watering or eye redness). 
Nasal Cytology 
  Subjects’ nasal smears were assessed to determine the 
percentage of eosinophils for stratification purposes. Slightly 
more than half of the subjects demonstrated <5% eosinophils 
in their nasal smear at baseline (Table 4 ). Mean percent 
eosinophils were comparable at baseline for both treatment 
groups. Mean percent eosinophils were lower for FFNS at 
the end of the study compared with placebo. 
Tolerability 
  Twenty-one subjects (40%) in the FFNS group and 18 
subjects (37%) in the placebo group reported adverse events. 
Most events were described as mild. The most commonly 
reported events (3% incidence and more common than 
placebo) were cough (6% vs 2%), migraine (4% vs 2%), 
nasal ulcer (4% vs 2%) and epistaxis (4% vs 0) for FFNS and 
placebo, respectively. All adverse events reported, except 
one event of increased transaminase, were  deemed  unrelated  
Table 2.  Trigger Questionnaire Responses 
 
Individual Triggers, n (%)  FFNS 110 mcg QD 
(N=53) 
Placebo 
(N=49) 
Total 
(N=102) 
Air Pollution 
Any 
Outside dust 
Exhaust (cars, trucks, buses) 
Smog 
Fumes and open burning 
Industrial gases/fumes 
 
53 (100) 
45 (85) 
43 (81) 
29 (55) 
33 (62) 
22 (42) 
 
49 (100) 
42 (86) 
40 (82) 
28 (57) 
29 (59) 
16 (33) 
 
102 (100) 
87 (85) 
83 (87) 
57 (56) 
62 (61) 
38 (37) 
Weather/Temperature Triggers 
Any 
Windy days 
Cold days 
Damp/rainy days 
Temperature changes 
Change in barometric pressure 
Hot summer days 
 
49 (92) 
9 (17) 
36 (68) 
29 (55) 
29 (55) 
11 (21) 
12 (23) 
 
46 (94) 
15 (31) 
29 (59) 
29 (59) 
30 (61) 
8 (16) 
9 (18) 
 
95 (93) 
24 (24) 
65 (64) 
58 (57) 
59 (58) 
19 (19) 
21 (21) 
Strong Odor Triggers 
Any 
Smoke (tobacco/burning items) 
Perfumes 
Cosmetics 
Cleaning products/detergents/soaps 
Paint fumes or paint products 
Hairspray 
Fumes from domestic space heating  
 
51 (96) 
47 (89) 
16 (30) 
9 (17) 
7 (13) 
30 (57) 
16 (30) 
18 (34) 
 
44 (90) 
35 (71) 
9 (18) 
4 (8) 
13 (27) 
23 (47) 
17 (35) 
13 (27)  
 
95 (93) 
82 (80) 
25 (25) 
13 (13) 
20 (20) 
53 (52) 
33 (32) 
31 (30) 96    The Open Respiratory Medicine Journal, 2010, Volume 4  Tantilipikorn et al. 
Table 3.  Weekly and Overall Mean Change from Baseline in 
Daily Reflective Total Nasal Symptom Score 
(rTNSS)  
 
  FFNS 110 mcg QD 
(N=53) 
Placebo 
(N=49) 
Baseline 
Mean (SE) 
Weeks 1 – 4 
Mean (SE) 
 
6.7 (0.17) 
4.4 (0.25) 
 
6.4 (0.17) 
4.4 (0.24) 
Week 1 
Mean change (SE) 
Week 2, n 
Mean change (SE) 
Week 3, n 
Mean change (SE) 
Week 4, n 
Mean change (SE) 
 
-1.6 (0.22) 
53 
-2.1 (0.26) 
51 
-2.5 (0.29) 
49 
-2.9 (0.30) 
 
-1.3 (0.19) 
49 
-1.8 (0.28) 
47 
-2.4 (0.28) 
46 
-2.8 (0.29) 
Weeks 1 – 4 
Mean change (SE) 
Least squares mean change (SE) 
Least squares mean difference 
p-value 
 
-2.2 (0.24) 
-2.17 (0.23) 
-0.065 
0.845 
 
-2.0 (0.24) 
-2.10 (0.25) 
to study drugs. In this event, the subject who was receiving 
FFNS experienced an increase in alanine aminotransferase 
(ALAT) from 8 to 97 U/L and a rise in aspartate 
aminotransferase (ASAT) from 13 to 44 U/L. This event was 
noticed at the final treatment visit. The subject was followed 
and the elevations were noted to be resolved 24 days later. 
DISCUSSION 
  In this randomized, placebo-controlled, pilot study which 
evaluated Thai subjects with a narrowly-defined condition, 
irritant rhinitis primarily triggered by air pollution, FFNS did 
not demonstrate efficacy in reducing the nasal symptoms of 
this condition. The lack of efficacy for FFNS in this study 
may be attributable to several factors. While the study 
attempted to obtain a pure irritant rhinitis population 
triggered by air pollution, 90% of subjects also reported 
specific types of weather/temperature and strong odor 
triggers. The actual study population aligns closely with the 
aforementioned classification of NAR where irritant rhinitis 
is a subset of VMR, a condition characterized by nonspecific 
nasal hyperreactivity in response to non-immunologic 
stimuli such as temperature, relative humidity, strong odors 
and other airborne irritants [7]. 
  This study highlights that the characteristics of this 
clinical population do not align with classification schemes 
that distinguish subtypes of NAR based on triggers alone. 
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Patients with NAR are likely to have several triggers and 
may, in addition, also have allergic rhinitis. Two previous 
randomized controlled trials of NAR found FFNS ineffective 
in subjects selected for weather/temperature-sensitive VMR 
[9]. Thus, results from this pilot study are not completely 
surprising in that the study population identified air pollution 
as their primary trigger, but nearly all subjects had other 
non-allergic triggers, including changes in the weather. Our 
study results do not rule out the possibility that FFNS may 
be effective for the symptoms of irritant rhinitis in subjects 
with isolated airborne irritant triggers or at a different dose, 
frequency of administration, or longer duration than shown 
to be effective for allergic rhinitis. In addition, confirmation 
of the subjects’ responses on the trigger questionnaire with 
nasal provocation challenges may have helped to further 
refine the study population. 
  The decision to conduct this pilot study in Thailand was 
based on historical air quality history, availability of air 
quality monitoring, the close proximity of investigative sites, 
and a temperate climate to avoid weather/temperature 
changes thought to precipitate VMR. Thailand currently uses 
the US Environmental Protection Agency (EPA) air quality 
assessment scale of 0 to 500 where an air quality index 
(AQI) value between 0 and 100 corresponds to an air quality 
standard of good (0-50) to moderate (51-100) which are 
considered satisfactory. For the majority of the study, weekly 
air quality fell within the moderate range at all sites, with 
some sites even demonstrating weekly levels below 50. 
Given the better than expected air quality, this study does not 
rule out an effect of FFNS in irritant rhinitis where exposure 
to air pollution is ensured. 
  Although subjects were required to meet minimum 
symptom criteria prior to randomization, those with more 
severe symptoms may have declined to participate due to the 
study requirement of withholding medications during the 
screening period. The moderate to severe symptom criteria 
for inclusion may have inadvertently permitted enrollment of 
chronic irritant rhinitis patients who consistently sustain a 
moderate irritation from the air pollution, when present, but 
never exacerbate to symptom levels high enough where a 
treatment difference versus placebo could be demonstrated. 
The possibility for this effect was increased in this study 
since the AQI never reached unhealthy levels consistently 
high enough to precipitate severe symptoms. The difficulty 
in demonstrating a treatment difference was also 
compounded by the moisturizing benefit of the placebo nasal 
spray administered just prior to subjects starting their day, a 
recurring influence in trials conducted with topically 
administered placebos. A placebo benefit is evidenced by the 
fact subjects in both treatment groups improved. 
  NAR subtypes are often distinguished by the presence or 
absence of nasal eosinophils but nasal cytology data from 
patients with irritant rhinitis triggered by respiratory irritants 
is lacking. The eosinophil cytology for the current study 
found over 50% of subjects in both groups had 5% or fewer 
eosinophils at baseline with nearly two-thirds having fewer 
than 20%. The observation that greater than half the subjects 
corresponded to a non-inflammatory population may provide 
an explanation for the inability to demonstrate a treatment 
difference with FFNS because eosinophilia has been 
suggested as a predictor of the effectiveness of intranasal 
corticosteroid therapy [12]. 
 
Fig. (3). Daily mean change from baseline in daily reflective total nasal symptom score over weeks 1 – 4. 98    The Open Respiratory Medicine Journal, 2010, Volume 4  Tantilipikorn et al. 
  If the symptomatology is elicited by a neurogenic 
mechanism in response to the pollution rather than an 
inflammatory process, FFNS would not be expected to have 
a therapeutic effect for subjects with irritant rhinitis. A 
neurogenic mechanism for NAR is supported by the findings 
that both parasympathetic and sympathetic neurons affect 
epithelial, vascular, as well as glandular functions in the nose 
[10]. 
CONCLUSION 
  The dose and duration of treatment with FFNS for 
seasonal and perennial allergic rhinitis was not effective for 
this population of subjects with irritant rhinitis caused 
predominantly by air pollution. These results, combined with 
two previous randomized controlled trials demonstrating 
FFNS to be ineffective in subjects selected for 
weather/temperature-sensitive VMR, suggest that intranasal 
corticosteroids may not be effective in subtypes of NAR 
where eosinophilic inflammation is not a major component 
[9]. Additional studies should investigate the 
pathophysiology of irritant rhinitis, other treatments or 
treatment combinations, including non-steroidal options, as 
well as other endpoints including biomarkers or change in 
nasal mucosa responsiveness to methacholine. 
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ABBREVIATIONS 
ALAT =  Alanine  aminotransferase 
AM =  Morning 
AQI =  Air  quality  index 
ASAT =  Aspartate  aminotransferase 
EPA =  Environmental  protection  agency 
FFNS  = Fluticasone furoate nasal spray 
iTNSS  = Instantaneous total nasal symptom score 
NAR =  Non-allergic  rhinitis 
NARES  = Non-allergic rhinitis with eosinophilia syndrome 
PM =  Evening 
rTNSS  = Reflective total nasal symptom score 
TNSS  = Total nasal symptom score 
TOSS  = Total ocular symptom score 
VMR =  Vasomotor  rhinitis 
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